Healthy adults
Conditions
Interventions
BVVR001 (development code) ingestion Twice a day (before bedtime and after wake-up) for 4 weeks ->
Washout for 5 weeks ->
Placebo ingestion Twice a day (before bedtime and after wake-up) for 4 weeks
Placebo ingestion Twice a day (before bedtime and after wake-up) for 4 weeks ->
BVVR001 (development code) ingestion Twice a day (before bedtime and after wake-up) for 4 weeks
Sponsors
Kao Corporation
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Healthy males
Exclusion criteria
Exclusion criteria: -Subjects who have been suffered from a critical disease -Subjects who take prescription medicine -Subjects with the illness of a vascular function -Subjects with atopic dermatitis, eczema and pollen allergy -Subjects with food allergy -Subjects with smoking habit -Subjects who are in poor physical condition -Subjects who have an abnormality of measurement skin site -Subjects undergoing trauma in the measurement site -Subjects who are influenced by the adhesive -Subjects who participate in the other examinations which have an influence on this examination -Subjects deemed inappropriate to participate in this study by the principle investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective indicators on skin microcirculation before and after ingestion of BVVR001 (development code) for 4 weeks | — |
Countries
Japan,Australia
Contacts
Public ContactDaiji Kagawa
Kao Corporation R&D -Core Technology- Biological Science Research
Outcome results
None listed